Integral Diagnostics (ASX:IDX) reported Wednesday attributable loss per diluted share in the fiscal first half narrowed to AU$0.0016, from a loss of AU$0.2862 per diluted share a year earlier.
Analysts polled by Visible Alpha were expecting earnings per share of AU$0.0006.
Revenue from ordinary activities for the six months Dec. 31, 2024, was AU$252.9 million, up 9% from AU$231.3 million in the same period last year. Analysts surveyed by Visible Alpha expected AU$250.6 million.
The radiologist and diagnostic imaging provider replacement and growth capital expenditure for the fiscal year to reach AU$60 million to AU$65 million.
The board declared an interim dividend of AU$0.025 per share, unchanged from the previous reported period, payable on April 7 to shareholders on record as of March 7.
Price (AUD): $2.86, Change: $-0.030, Percent Change: -1.04%
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。